Table 3. Summary of post-irradiation adjunct treatments.
| Characteristic | Group A Value (%)n = 99 | Group B Value (%)n = 44 |
|---|---|---|
| Cyclocryotherapy | 0 | 1 (2.27) |
| Enucleation | 3 (3.03) | 7 (15.91) |
| Photodynamic therapy | 1 (1.01) | 0 |
| Ru-106 brachytherapy | 2 (2.02) | 4 (9.09) |
| Retinal cryotherapy | 0 | 2 (4.55) |
| Retinal photocoagulation | 7 (7.07) | 7 (15.91) |
| TSCPC | 1 (1.01) | 0 |
| TTT for exsudation | 4 (4.44) | 3 (6.82) |
| TTT sandwich | 5 (5.05) | 19 (43.18) |
| TTT for recurrence | 5 (5.05) | 2 (4.55) |
| TTT for other reason | 1 (1.01) | 2 (4.55) |
| Vitrectomy with endoresection | 1 (1.01) | 8 (8.18) |
| Vitrectomy without endoresection | 6 (6.06) | 5 (11.36) |
| Anti-VEGF intravitreal treatment | 13 (13.13) | 4 (9.09) |
Table 3. showing an overview of adjunct treatments performed after ruthenium-106 plaque brachytherapy. TTT = transpupillary thermotherapy; "TTT for other reason" was performed in case of insufficient scaring along the tumor margin; TSCPC = transscleral cyclophotocoagulation; VEGF = vascular endothelial growth factor.